RNF105 Polyclonal Antibody, AbBy Fluor-350 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-22472R-BF350 |
| Product Name | RNF105 Polyclonal Antibody, AbBy Fluor-350 Conjugated |
| Applications |
IF
|
| Reactivity | Mouse, Rat |
| Predicted Reactivity | Human |
| Specifications | |
| Conjugation | AbBy Fluor-350 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human RNF105 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 7267 |
| Swiss Prot | P53804 |
| Subcellular location | Nucleus |
| Synonyms | DCRR1; E3 ubiquitin protein ligase TTC3; E3 ubiquitin-protein ligase TTC3; Protein DCRR1; RING finger protein 105;Tetratricopeptide repeat protein 3 (TPR repeat protein D); Tetratricopeptide repeat protein 3; TPR repeat protein 3; TPR repeat protein D; TPRD; TPRDI; TPRDII; TPRDIII; TTC3; TTC3_HUMAN. |
| Background | E3 ubiquitin-protein ligase that mediates the ubiquitination and subsequent degradation of phosphorylated Akt (AKT1, AKT2 and AKT3) in the nucleus. Acts as a terminal regulator of Akt signaling after activation; its phosphorylation by Akt, which is a prerequisite for ubiquitin ligase activity, suggests the existence of a regulation mechanism required to control Akt levels after activation. Catalyzes the formation of 'Lys-48'-polyubiquitin chains. May play a role in neuronal differentiation inhibition via its interaction with CIT. |
| Application Dilution | |
| IF | |